ANV600

DRUG2 trials

Sponsors

Anaveon AG

Conditions

Advanced Solid TumorAdvanced solid tumours

Phase 1

A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

CompletedNCT06470763

Anaveon AGAdvanced Solid Tumor

Start: 2024-07-01End: 2026-06-22Updated: 2026-07-10

A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)

RecruitingCTIS2023-509633-39-00

Anaveon AGAdvanced solid tumours

Start: 2024-08-06Target: 194Updated: 2025-07-29

Related Papers

Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-27

EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28